Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28199818

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2017 Feb 20
First author
Choueiri TK

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2017 Feb 20;35(6):577-579. doi: 10.1200/JCO.2016.71.0673.
    note
    Source null
    related pmid
    27992269
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2017 Jun 1;35(16):1859-1860. doi: 10.1200/JCO.2017.72.2629.
    note
    Source null
    related pmid
    28549224
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2017 Jun 1;35(16):1858-1859. doi: 10.1200/JCO.2016.71.6506.
    note
    Source null
    related pmid
    28549228
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2017 Nov 10;35(32):3736. doi: 10.1200/JCO.2017.76.3292.
    note
    Source null
    related pmid
    29112824
    relationship
    Erratum in
  5. citation
    J Clin Oncol. 2018 Feb 10;36(5):521. doi: 10.1200/JCO.2017.77.6526.
    note
    Source null
    related pmid
    29414281
    relationship
    Erratum in

Authors and identifiers

  1. name
    Choueiri TK
    type
    Author
  2. name
    Halabi S
    type
    Author
  3. name
    Sanford BL
    type
    Author
  4. name
    Hahn O
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Walsh MK
    type
    Author
  7. name
    Feldman DR
    type
    Author
  8. name
    Olencki T
    type
    Author
  9. name
    Picus J
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Dakhil S
    type
    Author
  12. name
    George DJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Choueiri TK
    type
    Author
  2. name
    Halabi S
    type
    Author
  3. name
    Sanford BL
    type
    Author
  4. name
    Hahn O
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Walsh MK
    type
    Author
  7. name
    Feldman DR
    type
    Author
  8. name
    Olencki T
    type
    Author
  9. name
    Picus J
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Dakhil S
    type
    Author
  12. name
    George DJ
    type
    Author
bibliography ids
  1. nci-bib-627598f92e4628f3f7037efa
book metadata
content sha256
a1d4614fabd4ba2ce32f973c84c2213bd34afdd17b3bb23b23aff22e8d414f68
document type
citation
dois
  1. 10.1200/JCO.2016.70.7398
electronic publication date
display
2016 Nov 14
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:28199818
immutable id
pubmed:28199818@a1d4614fabd4ba2ce32f973c84c2213bd34afdd17b3bb23b23aff22e8d414f68
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
6
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
591-597
volume
35
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2017 Feb 20;35(6):577-579. doi: 10.1200/JCO.2016.71.0673.
    note
    Source null
    related pmid
    27992269
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2017 Jun 1;35(16):1859-1860. doi: 10.1200/JCO.2017.72.2629.
    note
    Source null
    related pmid
    28549224
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2017 Jun 1;35(16):1858-1859. doi: 10.1200/JCO.2016.71.6506.
    note
    Source null
    related pmid
    28549228
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2017 Nov 10;35(32):3736. doi: 10.1200/JCO.2017.76.3292.
    note
    Source null
    related pmid
    29112824
    relationship
    Erratum in
  5. citation
    J Clin Oncol. 2018 Feb 10;36(5):521. doi: 10.1200/JCO.2017.77.6526.
    note
    Source null
    related pmid
    29414281
    relationship
    Erratum in
outcomes validated
false
pmid
28199818
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
31108779927001cf3ab6888be40b6feed5acb126074b4a0cb1d8fbe09580cf51
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Feb 20
precision
day
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28199818/
title
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Preserved source evidence · Not medical advice